The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Naiara Martínez-Vélez, Marc Garcia-Moure, Miguel Marigil, Marisol González-Huarriz, Montse Puigdelloses, Jaime Gallego Pérez-Larraya, Marta Zalacaín, Lucía Marrodán, Maider Varela-Guruceaga, Virginia Laspidea, Jose Javier Aristu, Luis Isaac Ramos, Sonia Tejada-Solís, Ricardo Díez-Valle, Chris Jones, Alan Mackay, Jose A. Martínez-Climent, Maria Jose García-Barchino, Eric Raabe, Michelle Monje & 10 others Oren J. Becher, Marie Pierre Junier, Elias A. El-Habr, Herve Chneiweiss, Guillermo Aldave, Hong Jiang, Juan Fueyo, Ana Patiño-García, Candelaria Gomez-Manzano, Marta M. Alonso

Research output: Contribution to journalArticle

Abstract

Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).

Original languageEnglish (US)
Article number2235
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Oncolytic Viruses
Pediatrics
viruses
Viruses
Glioma
mice
Tumors
tumors
grade
adenoviruses
Oncolytic Virotherapy
brain
emerging
Brain
Neoplasms
Phase II Clinical Trials
Clinical Trials, Phase I
Cells
Adenoviridae
Brain Neoplasms

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Martínez-Vélez, N., Garcia-Moure, M., Marigil, M., González-Huarriz, M., Puigdelloses, M., Gallego Pérez-Larraya, J., ... Alonso, M. M. (2019). The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature communications, 10(1), [2235]. https://doi.org/10.1038/s41467-019-10043-0

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. / Martínez-Vélez, Naiara; Garcia-Moure, Marc; Marigil, Miguel; González-Huarriz, Marisol; Puigdelloses, Montse; Gallego Pérez-Larraya, Jaime; Zalacaín, Marta; Marrodán, Lucía; Varela-Guruceaga, Maider; Laspidea, Virginia; Aristu, Jose Javier; Ramos, Luis Isaac; Tejada-Solís, Sonia; Díez-Valle, Ricardo; Jones, Chris; Mackay, Alan; Martínez-Climent, Jose A.; García-Barchino, Maria Jose; Raabe, Eric; Monje, Michelle; Becher, Oren J.; Junier, Marie Pierre; El-Habr, Elias A.; Chneiweiss, Herve; Aldave, Guillermo; Jiang, Hong; Fueyo, Juan; Patiño-García, Ana; Gomez-Manzano, Candelaria; Alonso, Marta M.

In: Nature communications, Vol. 10, No. 1, 2235, 01.12.2019.

Research output: Contribution to journalArticle

Martínez-Vélez, N, Garcia-Moure, M, Marigil, M, González-Huarriz, M, Puigdelloses, M, Gallego Pérez-Larraya, J, Zalacaín, M, Marrodán, L, Varela-Guruceaga, M, Laspidea, V, Aristu, JJ, Ramos, LI, Tejada-Solís, S, Díez-Valle, R, Jones, C, Mackay, A, Martínez-Climent, JA, García-Barchino, MJ, Raabe, E, Monje, M, Becher, OJ, Junier, MP, El-Habr, EA, Chneiweiss, H, Aldave, G, Jiang, H, Fueyo, J, Patiño-García, A, Gomez-Manzano, C & Alonso, MM 2019, 'The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models', Nature communications, vol. 10, no. 1, 2235. https://doi.org/10.1038/s41467-019-10043-0
Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature communications. 2019 Dec 1;10(1). 2235. https://doi.org/10.1038/s41467-019-10043-0
Martínez-Vélez, Naiara ; Garcia-Moure, Marc ; Marigil, Miguel ; González-Huarriz, Marisol ; Puigdelloses, Montse ; Gallego Pérez-Larraya, Jaime ; Zalacaín, Marta ; Marrodán, Lucía ; Varela-Guruceaga, Maider ; Laspidea, Virginia ; Aristu, Jose Javier ; Ramos, Luis Isaac ; Tejada-Solís, Sonia ; Díez-Valle, Ricardo ; Jones, Chris ; Mackay, Alan ; Martínez-Climent, Jose A. ; García-Barchino, Maria Jose ; Raabe, Eric ; Monje, Michelle ; Becher, Oren J. ; Junier, Marie Pierre ; El-Habr, Elias A. ; Chneiweiss, Herve ; Aldave, Guillermo ; Jiang, Hong ; Fueyo, Juan ; Patiño-García, Ana ; Gomez-Manzano, Candelaria ; Alonso, Marta M. / The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{e18e90b30d4f4212a3f35e0695d9303d,
title = "The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models",
abstract = "Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).",
author = "Naiara Mart{\'i}nez-V{\'e}lez and Marc Garcia-Moure and Miguel Marigil and Marisol Gonz{\'a}lez-Huarriz and Montse Puigdelloses and {Gallego P{\'e}rez-Larraya}, Jaime and Marta Zalaca{\'i}n and Luc{\'i}a Marrod{\'a}n and Maider Varela-Guruceaga and Virginia Laspidea and Aristu, {Jose Javier} and Ramos, {Luis Isaac} and Sonia Tejada-Sol{\'i}s and Ricardo D{\'i}ez-Valle and Chris Jones and Alan Mackay and Mart{\'i}nez-Climent, {Jose A.} and Garc{\'i}a-Barchino, {Maria Jose} and Eric Raabe and Michelle Monje and Becher, {Oren J.} and Junier, {Marie Pierre} and El-Habr, {Elias A.} and Herve Chneiweiss and Guillermo Aldave and Hong Jiang and Juan Fueyo and Ana Pati{\~n}o-Garc{\'i}a and Candelaria Gomez-Manzano and Alonso, {Marta M.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-10043-0",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

AU - Martínez-Vélez, Naiara

AU - Garcia-Moure, Marc

AU - Marigil, Miguel

AU - González-Huarriz, Marisol

AU - Puigdelloses, Montse

AU - Gallego Pérez-Larraya, Jaime

AU - Zalacaín, Marta

AU - Marrodán, Lucía

AU - Varela-Guruceaga, Maider

AU - Laspidea, Virginia

AU - Aristu, Jose Javier

AU - Ramos, Luis Isaac

AU - Tejada-Solís, Sonia

AU - Díez-Valle, Ricardo

AU - Jones, Chris

AU - Mackay, Alan

AU - Martínez-Climent, Jose A.

AU - García-Barchino, Maria Jose

AU - Raabe, Eric

AU - Monje, Michelle

AU - Becher, Oren J.

AU - Junier, Marie Pierre

AU - El-Habr, Elias A.

AU - Chneiweiss, Herve

AU - Aldave, Guillermo

AU - Jiang, Hong

AU - Fueyo, Juan

AU - Patiño-García, Ana

AU - Gomez-Manzano, Candelaria

AU - Alonso, Marta M.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).

AB - Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).

UR - http://www.scopus.com/inward/record.url?scp=85066314046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066314046&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-10043-0

DO - 10.1038/s41467-019-10043-0

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2235

ER -